Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Genome Diagnostics Laboratory, |
RCV001848506 | SCV002105321 | uncertain significance | Hereditary spastic paraplegia | 2019-12-01 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002543408 | SCV003247867 | uncertain significance | Infantile-onset ascending hereditary spastic paralysis | 2022-06-22 | criteria provided, single submitter | clinical testing | This sequence change replaces tyrosine, which is neutral and polar, with phenylalanine, which is neutral and non-polar, at codon 1607 of the ALS2 protein (p.Tyr1607Phe). This variant is present in population databases (rs370296035, gnomAD 0.0009%). This variant has not been reported in the literature in individuals affected with ALS2-related conditions. Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Tolerated"; PolyPhen-2: "Possibly Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |